Mass spectrometry, data re-analysis, and homology modelling predict posttranslational modifications of leucine-rich alpha-2-glycoprotein as a marker of myelodysplastic syndrome

0013404 2023 RIV NL eng J
Májek, Pavel^G - Sovová, Žofie - Pečánková, Klára - Čermák, Jaroslav - Gašová, Zdenka - Pecherková, Pavla - Ignjatovic, V. - Dyr, Jan Evangelista
Mass spectrometry, data re-analysis, and homology modelling predict posttranslational modifications of leucine-rich alpha-2-glycoprotein as a marker of myelodysplastic syndrome.
Cancer biomarkers. Vol. 34, no. 3 (2022), s. 485-492. ISSN 1574-0153
Grant: Grantová agentura ČR GA20-10845S
Institucionální podpora: RVO:00023736
Klíčová slova: MDS * LRG * leucine-rich alpha-2-glycoprotein * proteomics
Cite Score: 6.100, rok: 2022; SJR: 0.622, rok: 2022; IF: 3.1, rok: 2022
DOI: 10.3233/CBM-210033

Anotace: We report the presence of LRG proteoforms that correlate with diagnosis in the plasma of MDS patients. The combination of mass spectrometry, re-analysis of publicly available data, and homology modelling, represents an approach that can be used for any protein to predict clinically relevant protein sites for biomarker research despite the character of the PTMs being unknown.